{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T04:47:33Z","timestamp":1793767653289,"version":"4.6.1"},"reference-count":71,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2023,3,18]],"date-time":"2023-03-18T00:00:00Z","timestamp":1679097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,3,18]],"date-time":"2023-03-18T00:00:00Z","timestamp":1679097600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"GSK","award":["Study 209985"],"award-info":[{"award-number":["Study 209985"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dig Dis Sci"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1007\/s10620-023-07862-z","type":"journal-article","created":{"date-parts":[[2023,3,25]],"date-time":"2023-03-25T16:55:46Z","timestamp":1679763346000},"page":"2710-2730","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["Cholestatic Pruritus Treatments in Primary Biliary Cholangitis and Primary Sclerosing Cholangitis: A Systematic Literature Review"],"prefix":"10.1007","volume":"68","author":[{"given":"Helen T.","family":"Smith","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea Ribeiro","family":"de Souza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"April H.","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan M.","family":"McLaughlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John J.","family":"Dever","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie A.","family":"Myers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing Voon","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,3,18]]},"reference":[{"key":"7862_CR1","doi-asserted-by":"publisher","first-page":"e418","DOI":"10.3399\/bjgp15X685477","volume":"65","author":"VS Hegade","year":"2015","unstructured":"Hegade VS, Kendrick SF, Rehman J, Jones DE. Itch and liver: management in primary care. Br J Gen Pract. 2015;65:e418\u2013e420.","journal-title":"Br J Gen Pract."},{"key":"7862_CR2","doi-asserted-by":"publisher","first-page":"3418","DOI":"10.3748\/wjg.v23.i19.3418","volume":"23","author":"K Tajiri","year":"2017","unstructured":"Tajiri K, Shimizu Y. Recent advances in the management of pruritus in chronic liver diseases. World J Gastroenterol. 2017;23:3418\u20133426.","journal-title":"World J Gastroenterol."},{"key":"7862_CR3","doi-asserted-by":"crossref","unstructured":"Lindor KD, Kowdley KV, and Harrison ME. ACG Clinical Guideline: Primary Sclerosing Cholangitis. Am J Gastroenterol. 2015;110:646\u2013659; quiz 660.","DOI":"10.1038\/ajg.2015.112"},{"key":"7862_CR4","unstructured":"Mayo MJ, Carey E, Smith HT, et al. Impact of Pruritus on Quality of Life and Current Treatment Patterns in Patients with Primary Biliary Cholangitis. Dig Dis Sci. 2022."},{"key":"7862_CR5","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1016\/j.jfma.2016.05.006","volume":"115","author":"XY Jin","year":"2016","unstructured":"Jin XY, Khan TM. Quality of life among patients suffering from cholestatic liver disease-induced pruritus: A systematic review. J Formos Med Assoc. 2016;115:689\u2013702.","journal-title":"J Formos Med Assoc."},{"key":"7862_CR6","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1016\/S1089-3261(03)00105-3","volume":"7","author":"NV Bergasa","year":"2003","unstructured":"Bergasa NV. Pruritus and fatigue in primary biliary cirrhosis. Clin Liver Dis. 2003;7:879\u2013900.","journal-title":"Clin Liver Dis."},{"key":"7862_CR7","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1002\/hep.26909","volume":"60","author":"U Beuers","year":"2014","unstructured":"Beuers U, Kremer AE, Bolier R, Elferink RP. Pruritus in cholestasis: facts and fiction. Hepatology. 2014;60:399\u2013407.","journal-title":"Hepatology."},{"key":"7862_CR8","first-page":"615","volume":"7","author":"C Levy","year":"2011","unstructured":"Levy C. Management of pruritus in patients with cholestatic liver disease. Gastroenterol Hepatol (N Y). 2011;7:615\u2013617.","journal-title":"Gastroenterol Hepatol (N Y)."},{"key":"7862_CR9","doi-asserted-by":"crossref","unstructured":"Trivedi HD, Lizaola B, Tapper EB, and Bonder A. Management of pruritus in primary biliary cholangitis: a narrative review. Am J Med. 2017;130:744 e741\u2013744 e747.","DOI":"10.1016\/j.amjmed.2017.01.037"},{"key":"7862_CR10","doi-asserted-by":"crossref","unstructured":"Trivella J and Levy C. Safety considerations for the management of cholestatic itch. Expert Opin Drug Saf. 2021:1\u201310.","DOI":"10.1080\/14740338.2021.1915984"},{"key":"7862_CR11","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1055\/s-0039-1679918","volume":"39","author":"RA Shah","year":"2019","unstructured":"Shah RA, Kowdley KV. Mechanisms and treatments of pruritus in primary biliary cholangitis. Semin Liver Dis. 2019;39:209\u2013220.","journal-title":"Semin Liver Dis."},{"key":"7862_CR12","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1136\/bmjspcare-2020-002801","volume":"11","author":"FL Murray-Brown","year":"2021","unstructured":"Murray-Brown FL. Naltrexone for cholestatic itch: a systematic review. BMJ Support Palliat Care. 2021;11:217\u2013225.","journal-title":"BMJ Support Palliat Care."},{"key":"7862_CR13","doi-asserted-by":"crossref","unstructured":"EASL. EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis. J Hepatol. 2017;67:145\u2013172.","DOI":"10.1016\/j.jhep.2017.03.022"},{"key":"7862_CR14","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1002\/hep.30145","volume":"69","author":"KD Lindor","year":"2019","unstructured":"Lindor KD, Bowlus CL, Boyer J, Levy C, Mayo M. Primary biliary cholangitis: 2018 practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2019;69:394\u2013419.","journal-title":"Hepatology."},{"key":"7862_CR15","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/S0011-393X(01)80033-3","volume":"62","author":"H Yokomori","year":"2001","unstructured":"Yokomori H, Oda M, Ishii H. Effects of ursodeoxycholic acid and colestilan versus ursodeoxycholic acid alone on serum bile acids and pruritus: A randomized, open-label study. Curr Ther Res. 2001;62:221\u2013229.","journal-title":"Curr Ther Res."},{"key":"7862_CR16","unstructured":"European Medicines Agency. Questran Light 4g\/sachet Powder for Oral Suspension Summary of Product Characteristics Updated 19-Jan-2021 | Neon Healthcare Ltd. Available at: https:\/\/www.medicines.org.uk\/emc\/product\/10588\/smpc\/print. Accessed 15 August, 2022."},{"key":"7862_CR17","unstructured":"Cerner Multum. Questran Prescribing Information. Available at: https:\/\/www.drugs.com\/mtm\/questran.html. Accessed August 15, 2022."},{"key":"7862_CR18","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1007\/s11901-020-00517-x","volume":"19","author":"MM D\u00fcll","year":"2020","unstructured":"D\u00fcll MM, Kremer AE. Newer approaches to the management of pruritus in cholestatic liver disease. Curr Hepatol Rep. 2020;19:86\u201395.","journal-title":"Curr Hepatol Rep."},{"key":"7862_CR19","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1016\/j.jaad.2019.04.035","volume":"81","author":"SP Patel","year":"2019","unstructured":"Patel SP, Vasavda C, Ho B, Meixiong J, Dong X, Kwatra SG. Cholestatic pruritus: Emerging mechanisms and therapeutics. J Am Acad Dermatol. 2019;81:1371\u20131378.","journal-title":"J Am Acad Dermatol."},{"key":"7862_CR20","first-page":"992","volume":"9","author":"DC Eschler","year":"2010","unstructured":"Eschler DC, Klein PA. An evidence-based review of the efficacy of topical antihistamines in the relief of pruritus. J Drugs Dermatol. 2010;9:992\u2013997.","journal-title":"J Drugs Dermatol."},{"key":"7862_CR21","doi-asserted-by":"publisher","first-page":"6658","DOI":"10.1038\/s41598-018-25214-0","volume":"8","author":"S Al-Dury","year":"2018","unstructured":"Al-Dury S, Wahlstrom A, Wahlin S et al. Pilot study with IBAT inhibitor A4250 for the treatment of cholestatic pruritus in primary biliary cholangitis. Sci Rep. 2018;8:6658.","journal-title":"Sci Rep."},{"key":"7862_CR22","unstructured":"Clinicaltrials.gov. A study to evaluate efficacy and safety of an investigational drug named volixibat in patients with itching caused by primary biliary cholangitis (VANTAGE). Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05050136. Accessed August 15, 2022."},{"key":"7862_CR23","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1016\/S0140-6736(17)30319-7","volume":"389","author":"VS Hegade","year":"2017","unstructured":"Hegade VS, Kendrick SF, Dobbins RL et al. Effect of ileal bile acid transporter inhibitor GSK2330672 on pruritus in primary biliary cholangitis: a double-blind, randomised, placebo-controlled, crossover, phase 2a study. Lancet. 2017;389:1114\u20131123.","journal-title":"Lancet."},{"key":"7862_CR24","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1002\/hep4.1305","volume":"3","author":"MJ Mayo","year":"2019","unstructured":"Mayo MJ, Pockros PJ, Jones D et al. A randomized, controlled, phase 2 study of maralixibat in the treatment of itching associated with primary biliary cholangitis. Hepatol Commun. 2019;3:365\u2013381.","journal-title":"Hepatol Commun."},{"key":"7862_CR25","unstructured":"Levy C, Kendrick S, Bowlus CL, et al. GLIMMER trial: A randomized, double-blind, placebo-controlled study of linerixibat, an inhibitor of the ileal bile acid transporter, in the treatment of cholestatic pruritus in primary biliary cholangitis. Poster LP38. Presented at American Association for the Study of Liver Diseases. 13\u201316 November, 2020. Virtual."},{"key":"7862_CR26","unstructured":"Albireo. Albireo announces FDA approval of Bylvay\u2122 (odevixibat), the first drug treatment for patients with progressive familial intrahepatic cholestasis (PFIC). 2021."},{"key":"7862_CR27","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1016\/S2468-1253(17)30246-7","volume":"2","author":"D Jones","year":"2017","unstructured":"Jones D, Boudes PF, Swain MG et al. Seladelpar (MBX-8025), a selective PPAR-\u03b4 agonist, in patients with primary biliary cholangitis with an inadequate response to ursodeoxycholic acid: a double-blind, randomised, placebo-controlled, phase 2, proof-of-concept study. Lancet Gastroenterol Hepatol. 2017;2:716\u2013726.","journal-title":"Lancet Gastroenterol Hepatol."},{"key":"7862_CR28","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1016\/j.jhep.2021.01.013","volume":"74","author":"JM Schattenberg","year":"2021","unstructured":"Schattenberg JM, Pares A, Kowdley KV et al. A randomized placebo-controlled trial of elafibranor in patients with primary biliary cholangitis and incomplete response to UDCA. J Hepatol. 2021;74:1344\u20131354.","journal-title":"J Hepatol."},{"key":"7862_CR29","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1111\/liv.15039","volume":"42","author":"AE Kremer","year":"2022","unstructured":"Kremer AE, Mayo MJ, Hirschfield G et al. Seladelpar improved measures of pruritus, sleep, and fatigue and decreased serum bile acids in patients with primary biliary cholangitis. Liver Int. 2022;42:112\u2013123.","journal-title":"Liver Int."},{"key":"7862_CR30","unstructured":"CYMABAY T. FDA Lifts All Clinical Holds on Seladelpar. Available at: https:\/\/ir.cymabay.com\/press-releases\/detail\/485\/fda-lifts-all-clinical-holds-on-seladelpar. Accessed 5 December, 2022."},{"key":"7862_CR31","doi-asserted-by":"publisher","DOI":"10.1002\/9781119536604","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions","author":"JPT Higgins","year":"2019","unstructured":"Higgins JPT, Thomas J, Chandler J et al. Cochrane Handbook for Systematic Reviews of Interventions, 2nd edn. Chichester (UK): John Wiley & Sons; 2019.","edition":"2"},{"key":"7862_CR32","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/S1697-2600(13)70017-6","volume":"13","author":"A Jarde","year":"2013","unstructured":"Jarde A, Losilla JM, Vives J, Rodrigo M. Q-Coh: A tool to screen the methodological quality of cohort studies in systematic reviews and meta-analyses. Int J Clin Health Psychol. 2013;13:138\u2013146.","journal-title":"Int J Clin Health Psychol."},{"key":"7862_CR33","first-page":"7","volume":"7","author":"LL Ma","year":"2020","unstructured":"Ma LL, Wang YY, Yang ZH, Huang D, Weng H, Zeng XT. Methodological quality (risk of bias) assessment tools for primary and secondary medical studies: what are they and which is better? Mil Med Res. 2020;7:7.","journal-title":"Mil Med Res."},{"key":"7862_CR34","doi-asserted-by":"publisher","first-page":"217","DOI":"10.2174\/1574887114666190328130720","volume":"14","author":"S Ataei","year":"2019","unstructured":"Ataei S, Kord L, Larki A et al. Comparison of sertraline with rifampin in the treatment of cholestatic pruritus: a randomized clinical trial. Rev Recent Clin Trials. 2019;14:217\u2013223.","journal-title":"Rev Recent Clin Trials."},{"key":"7862_CR35","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1016\/S0140-6736(89)91608-5","volume":"1","author":"L Bachs","year":"1989","unstructured":"Bachs L, Pares A, Elena M, Piera C, Rodes J. Comparison of rifampicin with phenobarbitone for treatment of pruritus in biliary cirrhosis. Lancet. 1989;1:574\u2013576.","journal-title":"Lancet."},{"key":"7862_CR36","doi-asserted-by":"publisher","first-page":"2077","DOI":"10.1016\/0016-5085(92)90335-V","volume":"102","author":"L Bachs","year":"1992","unstructured":"Bachs L, Pares A, Elena M, Piera C, Rodes J. Effects of long-term rifampicin administration in primary biliary cirrhosis. Gastroenterology. 1992;102:2077\u20132080.","journal-title":"Gastroenterology."},{"key":"7862_CR37","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1016\/0016-5085(92)90102-5","volume":"102","author":"NV Bergasa","year":"1992","unstructured":"Bergasa NV, Talbot TL, Alling DW et al. A controlled trial of naloxone infusions for the pruritus of chronic cholestasis. Gastroenterology. 1992;102:544\u2013549.","journal-title":"Gastroenterology."},{"key":"7862_CR38","doi-asserted-by":"publisher","first-page":"310","DOI":"10.7326\/0003-4819-82-3-310","volume":"82","author":"JR Bloomer","year":"1975","unstructured":"Bloomer JR, Boyer JL. Phenobarbital effects in cholestatic liver diseases. Ann Intern Med. 1975;82:310\u2013317.","journal-title":"Ann Intern Med."},{"key":"7862_CR39","doi-asserted-by":"publisher","first-page":"2171","DOI":"10.1056\/NEJMoa1714519","volume":"378","author":"C Corpechot","year":"2018","unstructured":"Corpechot C, Chazouilleres O, Rousseau A et al. A placebo-controlled trial of bezafibrate in primary biliary cholangitis. N Engl J Med. 2018;378:2171\u20132181.","journal-title":"N Engl J Med."},{"key":"7862_CR40","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/S0016-5085(66)80071-9","volume":"50","author":"DV Datta","year":"1966","unstructured":"Datta DV, Sherlock S. Cholestyramine for long term relief of the pruritus complicating intrahepatic cholestasis. Gastroenterology. 1966;50:323\u2013332.","journal-title":"Gastroenterology."},{"key":"7862_CR41","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1136\/bmj.289.6436.22","volume":"289","author":"JS Duncan","year":"1984","unstructured":"Duncan JS, Kennedy HJ, Triger DR. Treatment of pruritus due to chronic obstructive liver disease. Br Med J (Clin Res Ed). 1984;289:22.","journal-title":"Br Med J (Clin Res Ed)."},{"key":"7862_CR42","first-page":"731","volume":"16","author":"ACM Floreani","year":"1988","unstructured":"Floreani ACM, Zagolin M, Naccarato R. Diethylaminoethyldextran (DEAE-Dextran) for itching in primary biliary cirrhosis: a double blind trial. Med Sci Res. 1988;16:731.","journal-title":"Med Sci Res."},{"key":"7862_CR43","doi-asserted-by":"crossref","unstructured":"Ghent CN and Carruthers SG. Treatment of pruritus in primary biliary cirrhosis with rifampin. Results of a double-blind, crossover, randomized trial. Gastroenterology. 1988;94:488\u2013493.","DOI":"10.1016\/0016-5085(88)90442-8"},{"key":"7862_CR44","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1007\/s00535-002-1102-7","volume":"38","author":"T Kanda","year":"2003","unstructured":"Kanda T, Yokosuka O, Imazeki F, Saisho H. Bezafibrate treatment: a new medical approach for PBC patients? J Gastroenterol. 2003;38:573\u2013578.","journal-title":"J Gastroenterol."},{"key":"7862_CR45","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1002\/hep.23821","volume":"52","author":"EM Kuiper","year":"2010","unstructured":"Kuiper EM, van Erpecum KJ, Beuers U et al. The potent bile acid sequestrant colesevelam is not effective in cholestatic pruritus: results of a double-blind, randomized, placebo-controlled trial. Hepatology. 2010;52:1334\u20131340.","journal-title":"Hepatology."},{"key":"7862_CR46","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/j.clinre.2018.06.009","volume":"42","author":"S Lemoinne","year":"2018","unstructured":"Lemoinne S, Pares A, Reig A et al. Primary sclerosing cholangitis response to the combination of fibrates with ursodeoxycholic acid: French-Spanish experience. Clin Res Hepatol Gastroenterol. 2018;42:521\u2013528.","journal-title":"Clin Res Hepatol Gastroenterol."},{"key":"7862_CR47","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1111\/j.1365-2036.2010.04512.x","volume":"33","author":"C Levy","year":"2011","unstructured":"Levy C, Peter JA, Nelson DR et al. Pilot study: fenofibrate for patients with primary biliary cirrhosis and an incomplete response to ursodeoxycholic acid. Aliment Pharmacol Ther. 2011;33:235\u2013242.","journal-title":"Aliment Pharmacol Ther."},{"key":"7862_CR48","first-page":"57","volume":"65","author":"AS Loginov","year":"1993","unstructured":"Loginov AS, Reshetniak VI. and Petrakov AV [The treatment of primary biliary liver cirrhosis with rifampicin]. Ter Arkh 1993;65:57\u201362.","journal-title":"Ter Arkh"},{"key":"7862_CR49","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1002\/hep.21553","volume":"45","author":"MJ Mayo","year":"2007","unstructured":"Mayo MJ, Handem I, Saldana S, Jacobe H, Getachew Y, Rush AJ. Sertraline as a first-line treatment for cholestatic pruritus. Hepatology. 2007;45:666\u2013674.","journal-title":"Hepatology."},{"key":"7862_CR50","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1002\/hep4.1209","volume":"2","author":"MJ Mayo","year":"2018","unstructured":"Mayo MJ, Wigg AJ, Leggett BA et al. NGM282 for treatment of patients With primary biliary cholangitis: a multicenter, randomized, double-blind, placebo-controlled trial. Hepatol Commun. 2018;2:1037\u20131050.","journal-title":"Hepatol Commun."},{"key":"7862_CR51","doi-asserted-by":"publisher","first-page":"E151","DOI":"10.1016\/S0618-8278(19)30267-1","volume":"70","author":"MJ Mayo","year":"2019","unstructured":"Mayo MJ, Ling L, Hudgens S et al. LBP-21-Effect of NGM282, an FGF19 analogue, on pruritus in patients with primary sclerosing cholangitis: analysis of a phase, multicenter, randomized, double-blind, placebo-controlled trial. J Hepatol. 2019;70:E151.","journal-title":"J Hepatol."},{"key":"7862_CR52","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1111\/j.1365-2036.2005.02430.x","volume":"21","author":"JW O'Donohue","year":"2005","unstructured":"O\u2019Donohue JW, Pereira SP, Ashdown AC, Haigh CG, Wilkinson JR, Williams R. A controlled trial of ondansetron in the pruritus of cholestasis. Aliment Pharmacol Ther. 2005;21:1041\u20131045.","journal-title":"Aliment Pharmacol Ther."},{"key":"7862_CR53","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1007\/BF01300759","volume":"36","author":"A Podesta","year":"1991","unstructured":"Podesta A, Lopez P, Terg R et al. Treatment of pruritus of primary biliary cirrhosis with rifampin. Dig Dis Sci. 1991;36:216\u2013220.","journal-title":"Dig Dis Sci."},{"key":"7862_CR54","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1038\/ajg.2017.287","volume":"113","author":"A Reig","year":"2018","unstructured":"Reig A, Sese P, Pares A. Effects of bezafibrate on outcome and pruritus in primary biliary cholangitis with suboptimal ursodeoxycholic acid response. Am J Gastroenterol. 2018;113:49\u201355.","journal-title":"Am J Gastroenterol."},{"key":"7862_CR55","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1111\/j.1365-2125.1980.tb01742.x","volume":"10","author":"JA Summerfield","year":"1980","unstructured":"Summerfield JA. Naloxone modulates the perception of itch in man. Br J Clin Pharmacol. 1980;10:180\u2013183.","journal-title":"Br J Clin Pharmacol."},{"key":"7862_CR56","doi-asserted-by":"publisher","first-page":"e56","DOI":"10.1097\/MJT.0000000000000102","volume":"24","author":"JH Tabibian","year":"2017","unstructured":"Tabibian JH, Gossard A, El-Youssef M et al. Prospective clinical trial of rifaximin therapy for patients with primary sclerosing cholangitis. Am J Ther. 2017;24:e56\u2013e63.","journal-title":"Am J Ther."},{"key":"7862_CR57","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1097\/00042737-199406000-00015","volume":"6","author":"AS Taha","year":"1994","unstructured":"Taha AS, Allison MC, Myara A, Trivin F, Duncan A, Russell RI. Does cholestyramine reduce the efficacy of ursodeoxycholic acid in primary biliary cirrhosis? Eur J Gastroenterol Hepatol. 1994;6:535\u2013538.","journal-title":"Eur J Gastroenterol Hepatol."},{"key":"7862_CR58","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1016\/S0168-8278(02)00318-5","volume":"37","author":"R Terg","year":"2002","unstructured":"Terg R, Coronel E, Sorda J, Munoz AE, Findor J. Efficacy and safety of oral naltrexone treatment for pruritus of cholestasis, a crossover, double blind, placebo-controlled study. J Hepatol. 2002;37:717\u2013722.","journal-title":"J Hepatol."},{"key":"7862_CR59","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1136\/bmj.297.6662.1501","volume":"297","author":"JR Thornton","year":"1988","unstructured":"Thornton JR, Losowsky MS. Opioid peptides and primary biliary cirrhosis. BMJ. 1988;297:1501\u20131504.","journal-title":"BMJ."},{"key":"7862_CR60","doi-asserted-by":"publisher","first-page":"S63","DOI":"10.1016\/0168-8278(90)91587-M","volume":"11","author":"J Turner","year":"1990","unstructured":"Turner J, Rawlins M, Nagy J, James O. Flumecinol improves pruritus in cholestatic liver disease - a double blind placebo controlled trial. J Hepatol. 1990;11:S63.","journal-title":"J Hepatol."},{"key":"7862_CR61","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1111\/j.1365-2036.1994.tb00297.x","volume":"8","author":"IB Turner","year":"1994","unstructured":"Turner IB, Rawlins MD, Wood P, James OF. Flumecinol for the treatment of pruritus associated with primary biliary cirrhosis. Aliment Pharmacol Ther. 1994;8:337\u2013342.","journal-title":"Aliment Pharmacol Ther."},{"key":"7862_CR62","first-page":"1074","volume":"118","author":"GP van Berge Henegouwen","year":"1974","unstructured":"van Berge Henegouwen GP, Brandt KH. Cholestyramine therapy in intrahepatic cholestasis. Ned Tijdschr Geneeskd. 1974;118:1074\u20131079.","journal-title":"Ned Tijdschr Geneeskd."},{"key":"7862_CR63","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1016\/j.amjmed.2005.05.031","volume":"118","author":"AG Villamil","year":"2005","unstructured":"Villamil AG, Bandi JC, Galdame OA, Gerona S, Gadano AC. Efficacy of lidocaine in the treatment of pruritus in patients with chronic cholestatic liver diseases. Am J Med. 2005;118:1160\u20131163.","journal-title":"Am J Med."},{"key":"7862_CR64","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1111\/apt.14579","volume":"47","author":"GJ Webb","year":"2018","unstructured":"Webb GJ, Rahman SR, Levy C, Hirschfield GM. Low risk of hepatotoxicity from rifampicin when used for cholestatic pruritus: a cross-disease cohort study. Aliment Pharmacol Ther. 2018;47:1213\u20131219.","journal-title":"Aliment Pharmacol Ther."},{"key":"7862_CR65","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1053\/gast.1997.v113.pm9322521","volume":"113","author":"FH Wolfhagen","year":"1997","unstructured":"Wolfhagen FH, Sternieri E, Hop WC, Vitale G, Bertolotti M, Van Buuren HR. Oral naltrexone treatment for cholestatic pruritus: a double-blind, placebo-controlled study. Gastroenterology. 1997;113:1264\u20131269.","journal-title":"Gastroenterology."},{"key":"7862_CR66","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1007\/s00535-018-1465-z","volume":"53","author":"M Yagi","year":"2018","unstructured":"Yagi M, Tanaka A, Namisaki T et al. Is patient-reported outcome improved by nalfurafine hydrochloride in patients with primary biliary cholangitis and refractory pruritus? A post-marketing, single-arm, prospective study. J Gastroenterol. 2018;53:1151\u20131158.","journal-title":"J Gastroenterol."},{"key":"7862_CR67","first-page":"659","volume":"49","author":"M Zuin","year":"1991","unstructured":"Zuin M, Grandinetti G, Camisasca M et al. A comparison of cholestyramine and diethylaminoethyl-dextran for the treatment of hyperlipidemia and pruritus of primary biliary cirrhosis. Curr Ther Res. 1991;49:659\u2013665.","journal-title":"Curr Ther Res."},{"key":"7862_CR68","unstructured":"de Vries E, Bolier R, Goet J, et al. Bezafibrate is more effective than placebo in pruritus of chronic cholestasis: the FITCH trial. Hepatology. 2019;70."},{"key":"7862_CR69","doi-asserted-by":"crossref","unstructured":"Dervout C, Boulais N, Barnetche T, Nousbaum JB, Brenaut E, and Misery L. Efficacy of Treatments for Cholestatic Pruritus: A Systemic Review and Meta-analysis. Acta Derm Venereol. 2022;102:adv00653.","DOI":"10.2340\/actadv.v102.310"},{"key":"7862_CR70","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1002\/hep4.1567","volume":"4","author":"HP Kim","year":"2020","unstructured":"Kim HP, Lieber SR, Rogers ME et al. A systematic review of patient-reported outcomes in primary biliary cholangitis and primary sclerosing cholangitis. Hepatol Commun. 2020;4:1502\u20131515.","journal-title":"Hepatol Commun."},{"key":"7862_CR71","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.g7647","volume":"350","author":"L Shamseer","year":"2015","unstructured":"Shamseer L, Moher D, Clarke M et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ. 2015;350:g7647.","journal-title":"BMJ."}],"container-title":["Digestive Diseases and Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-023-07862-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10620-023-07862-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-023-07862-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,16]],"date-time":"2023-05-16T05:28:22Z","timestamp":1684214902000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10620-023-07862-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,18]]},"references-count":71,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["7862"],"URL":"https:\/\/doi.org\/10.1007\/s10620-023-07862-z","relation":{},"ISSN":["0163-2116","1573-2568"],"issn-type":[{"value":"0163-2116","type":"print"},{"value":"1573-2568","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,18]]},"assertion":[{"value":"16 September 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 January 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"HTS, ARdS and MMM are employees of GSK and hold stocks\/shares in the company. AHT was an employee of GSK at the time of the study and holds GSK stocks\/shares. JAM is an employee of Medical Decision Modelling Inc., which is a health economic firm commissioned by GSK to conduct this research. JJD and JVC were employees of Medical Decision Modelling Inc. at the time of the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}